Deconvolution sample size and design issues [Power / Sample Size]

posted by mittyri – Russia, 2023-02-09 15:40 (440 d 18:04 ago) – Posting: # 23450
Views: 2,006

Dear all!

I am puzzled with EMA MR Guide:

5.1.1. It should be demonstrated that the modified release formulation has the claimed release characteristics. It is encouraged to employ deconvolution of the concentration-time data for the modified release formulation against an appropriate immediate release formulation (see Appen­dix II for more detail) in order to obtain the cumulative absorption (or in vivo release) versus time profile for the modified release formulation.

I looked into Appendix II, it is named as "in vivo skin adhesion", nothing more. Is there another Appendix I missed?

1. Is it possible to evaluate the number of subjects used for the following cumulative absorption estimate?
2. Is it possible to get exp1/A1/exp2/A2 terms from non-IV data (say IR)?
3. Are there any examples of designs to be used for Deconvolution? As far as I can see, 3 periods are necessary, IV, IR, MR
4. I see many papers explaining deconvolution in range of IVIVC, are there any examples of EPARs you know where deconvolution is used clearly 'to obtain the cumulative absorption (or in vivo release) versus time profile for the modified release formulation'

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,656 registered users;
120 visitors (0 registered, 120 guests [including 5 identified bots]).
Forum time: 10:45 CEST (Europe/Vienna)

Never never never never use Excel.
Not even for calculation of arithmetic means.    Martin Wolfsegger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5